About GEN inCode
GEN inCode is a company based in Manchester (United Kingdom) founded in 2018 by Jordi Puig.. GEN inCode has raised $5.46 million across 4 funding rounds from investors including Downing and Maven Capital Partners. GEN inCode has completed 1 acquisition, including Abcodia. GEN inCode offers products and services including CARDIO inCode-Score, LIPID inCode, SUDD inCode, THROMBO inCode, and ROCA test. GEN inCode operates in a competitive market with competitors including Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others.
- Headquarter Manchester, United Kingdom
- Founders Jordi Puig
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Genincode Plc
-
Annual Revenue
$3.38 M (USD)25.05as on Dec 31, 2024
-
Net Profit
$-5.55 M (USD)36.8as on Dec 31, 2024
-
EBITDA
$-6.06 M (USD)28.76as on Dec 31, 2024
-
Total Equity Funding
$5.46 M (USD)
in 4 rounds
-
Latest Funding Round
$5.07 M (USD), Post-IPO
Dec 21, 2023
-
Investors
Downing
& 1 more
-
Employee Count
Employee Count
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of GEN inCode
GEN inCode is a publicly listed company on the LSE with ticker symbol GENI in UK, operating in the Technology services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of GEN inCode
GEN inCode offers a comprehensive portfolio of products and services, including CARDIO inCode-Score, LIPID inCode, SUDD inCode, THROMBO inCode, and ROCA test. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Assesses cardiovascular risk using genetic and clinical data.
Evaluates genetic risks related to lipid disorders.
Analyzes genetic factors for sudden death risk.
Identifies thrombosis-related genetic risks.
Provides risk assessment for ovarian cancer.
Unlock access to complete
Funding Insights of GEN inCode
GEN inCode has successfully raised a total of $5.46M across 4 strategic funding rounds. The most recent funding activity was a Post-IPO round of $5.07 million completed in December 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Post-IPO — $5.1M
-
First Round
First Round
(28 Jan 2020)
- Investors Count 2
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2023 | Amount | Post-IPO - GEN inCode | Valuation |
investors |
|
| Aug, 2021 | Amount | Post-IPO - GEN inCode | Valuation |
investors |
|
| Aug, 2020 | Amount | Series A - GEN inCode | Valuation | Maven Capital Partners , Downing |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in GEN inCode
GEN inCode has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Downing and Maven Capital Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are targeted for private equity investments.
|
Founded Year | Domain | Location | |
|
Inheritance tax relief, funds, and bonds are provided across sectors.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by GEN inCode
GEN inCode has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Abcodia. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Provides ROCA test for early ovarian cancer screening and clinician resources.
|
2010 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - GEN inCode
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Gen Incode Comparisons
Competitors of GEN inCode
GEN inCode operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, Poseida Therapeutics, Castle Biosciences, Juno Therapeutics and Unity Biotechnology, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| domain | founded_year | HQ Location |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for aging diseases are developed by targeting senescent cells.
|
|
| domain | founded_year | HQ Location |
Diagnostic services are provided through laboratories and radiology units.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Gen Incode
Frequently Asked Questions about GEN inCode
When was GEN inCode founded?
GEN inCode was founded in 2018 and raised its 1st funding round 2 years after it was founded.
Where is GEN inCode located?
GEN inCode is headquartered in Manchester, United Kingdom. It is registered at Manchester, Greater Manchester, United Kingdom.
Is GEN inCode a funded company?
GEN inCode is a funded company, having raised a total of $5.46M across 4 funding rounds to date. The company's 1st funding round was a Series A of $4.48M, raised on Jan 28, 2020.
What is the annual revenue of GEN inCode?
Annual revenue of GEN inCode is $3.38M as on Dec 31, 2024.
What does GEN inCode do?
Founded in 2018 and based in Manchester, United Kingdom, GEN inCode operates in the precision medicine sector focused on cardiovascular health. Solutions for preventing and treating cardiovascular disease risks are provided through algorithms and machine learning models. These enable accurate assessment of patients clinical and genetic risks by healthcare professionals. The companys domain is genincode.com.
Who are the top competitors of GEN inCode?
GEN inCode's top competitors include Juno Therapeutics, Poseida Therapeutics and Denali Therapeutics.
What products or services does GEN inCode offer?
GEN inCode offers CARDIO inCode-Score, LIPID inCode, SUDD inCode, THROMBO inCode, and ROCA test.
Is GEN inCode publicly traded?
Yes, GEN inCode is publicly traded on LSE under the ticker symbol GENI.
How many acquisitions has GEN inCode made?
GEN inCode has made 1 acquisition, including Abcodia.
Who are GEN inCode's investors?
GEN inCode has 2 investors. Key investors include Downing, and Maven Capital Partners.
What is GEN inCode's ticker symbol?
The ticker symbol of GEN inCode is GENI on LSE.